Reuters

(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.

US FDA says all doses of Lilly's weight-loss and diabetes drug are now available

Apple Valley News Now

(CNN) — Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply as it sees continued high demand.

Lilly launches lower-price weight loss drug without injector pen

Insider

Eli Lilly is now offering cheaper single-dose vials of its wildly popular weight-loss drug Zepbound (tirzepatide), previously listed at $1,059 at month.

Eli Lilly just halved the price of its weight-loss drug — declaring war on the booming market of knockoffs

Ozempic and Wegovy may have some new competition. Eli Lilly has announced that its new diabetes drug, Zepbound (tirzepatide), reduced the risk of developing Type 2 diabetes by 94% in prediabetic adults in a clinical trial. Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment period, with...

Eli Lilly says its new diabetes drug was 94% effective in clinical trials

Federal drug safety regulators have received nearly 300,000 adverse event reports involving health problems with Ozempic, Wegovy, Mounjaro and similar drugs from the same class of medications, highlighting the growing concerns about side effects associated with the widely used diabetes and weight loss treatments. In a report published last week...

FDA Database Reveals High Number of Severe Adverse Events Involving Problem from Ozempic, Similar GLP1 Drugs

Eli Lilly LLY announced on Tuesday that it is now offering the two lowest doses of its popular weight loss drug Zepbound at approximately half the original price. The pharma giant said it has launched a single-dose vial option for Zepbound in an effort to meet soaring demand of the treatment. The lowered prices also make Zepbound more competitive with cheaper off-brand versions of the medication.

Eli Lilly just cut some Zepbound prices in half — but there's a catch

Axios

Nvidia, the most important stock in the world according to many on Wall Street, handily beat expectations Wednesday afternoon in an earnings report that reflects rising investments in AI across broad parts of the economy. Why it matters: The company has become synonymous with AI, but that doesn't mean it...

Nvidia earnings deliver, but shares slide after hours

NBC News

Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints. Two key changes to how people get and use the cheaper medicine, however, might not be appealing to some patients.

Lilly slashes prices on two lowest doses of Zepbound — if you're willing to give up injector pen

People are excited to use semaglutide, a diabetes drug popular for assisting weight loss that's commonly sold as Ozempic and Wegovy — and there's good reason to be. But the Food and Drug Administration is now warning the public not to get carried away, issuing an alert that it's received reports of people getting hospitalized after overdosing on the drug, in some cases taking up to 20 times the recommended dosage.

FDA Says People Are Taking 20 Times the Proper Dose of Ozempic and Overdosing

Eli Lilly (LLY) said Tuesday that the drug behind Zepbound was found to help nearly eliminate the risk of diabetes for adults who are pre-diabetic and are overweight or obese. The medication, tirzepatide, is sold by the company in the United States as Mounjaro for diabetes and Zepbound for weight loss.

Eli Lilly's weight loss drug almost eliminates the risk of diabetes in overweight adults

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

NewsNinja

A lady is cautioning others about purchasing budget earrings from Amazon, Shein, and H&M, after she experienced keloid formations on her earlobes due to wearing them. On a TikTok post that has garnered more than 334,000 likes, Sailor Rozema (@sailor.rozema), a content creator, shares a warning with her community of "dangly earring girls": the inexpensive jewelry found in fast fashion can have negative impacts on your well-being.

‘I’ll never be wearing earrings for the rest of my life’: Customer warns against buying from Shein

New York Post

Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs.

The more affordable vials are marketed toward patients whose health insurance will not reimburse them for weight-loss medications.

The drugmaker said it will sell 2.5 milligram and 5 milligram vials – now the two lowest doses of Zepbound – for $399 and $549 for a month’s supply on its website, LillyDirect. 



Lilly and its Danish rival Novo Nordisk have struggled to keep up with skyrocketing demand. 

Zepbound and Novo’s Wegovy have faced shortages for...

Eli Lilly slashes price of weight-loss drug Zepbound by 50% to sell in smaller doses

Healthline

Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more. Consumers who pay for medications out of pocket without insurance must purchase these products through the LillyDirect program and must also have a valid prescription from their healthcare provider.

Eli Lilly Cuts Zepbound Prices by 50% With Single-Dose Vials: What to Know

Several major companies are no longer publicly committing to a longstanding corporate pledge to provide a beneficial work environment to LGBTQ+ employees. Why it matters: It's a concrete sign of how the anti-DEI movement is roiling corporate America. Driving the news: Ford today confirmed it's the latest company to withdraw...

Anti-DEI movement gaining steam as Ford exits LGBTQ+ index

There are tens of millions of people in the U.S. taking the cholesterol-lowering medications known as statins to prevent heart disease. This could be because the U.S. Preventative Services Task Force advises healthcare professionals to prescribe statins in patients ages 40 to 75 who have at least one risk factor for heart disease, such as diabetes or dyslipidemia, and an estimated 10-year cardiovascular risk of 10 percent or more.

Glaucoma joins growing list of statin side effects

Eli Lilly has released a cheaper version of its weight-loss drug Zepbound. It will now be available in single-dose vials at about half the price. Instead of using prefilled injection pens, people will use a syringe to draw out the medicine. This option is available exclusively to people who pay out of pocket through LillyDirect, the company's platform that helps coordinate telehealth services and fill prescriptions.

Eli Lilly releases discounted single-dose vials of Zepbound weight-loss drug

Viking Therapeutics (VKTX) is one of several pharma companies racing to break up the weight loss drug duopoly currently held by Ozempic-maker Novo Nordisk (NVO) and Eli Lilly (LLY), the producer of Zepbound. Suggested Reading. With both an injection and weight loss pill in development, investors are taking notice of...

An Ozempic rival is 'onto something pretty amazing' with experimental weight loss drugs, investor says

(Reuters) - Pfizer Inc is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses. The drugmaker said on Tuesday that it launched the site called PfizerForAll to help patients get access to treatments like its COVID-19 drug Paxlovid and its migraine pill Nurtec by offering services like telehealth appointments and diagnostic tests.

Pfizer launches new website for migraine, respiratory offerings

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge for AstraZeneca's blockbuster drug Tagrisso.

J&J's chemotherapy-free treatment for lung cancer gets US approval

Fox Business

Those who need to carry epinephrine to treat potentially deadly allergic reactions now have an alternative option to an injection device.

FDA moves the needle, approves first nasal spray for treatment of severe allergic reactions

NewsBreak

Pfizer joins direct-to-consumer drug sales

Pfizer on Tuesday became the latest major drugmaker to sell medicine directly to consumers, launching a digital platform that's initially directed at people with migraines and...

Pfizer joins direct-to-consumer drug sales

Comments / 0